KR101834033B1 - 주의력 결핍 장애 치료용 고체 경구 제약 조성물 - Google Patents

주의력 결핍 장애 치료용 고체 경구 제약 조성물 Download PDF

Info

Publication number
KR101834033B1
KR101834033B1 KR1020137027522A KR20137027522A KR101834033B1 KR 101834033 B1 KR101834033 B1 KR 101834033B1 KR 1020137027522 A KR1020137027522 A KR 1020137027522A KR 20137027522 A KR20137027522 A KR 20137027522A KR 101834033 B1 KR101834033 B1 KR 101834033B1
Authority
KR
South Korea
Prior art keywords
delete delete
hours
release
sustained release
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137027522A
Other languages
English (en)
Korean (ko)
Other versions
KR20140030158A (ko
Inventor
데이빗 리크리쉬
펭 장
Original Assignee
아이언쇼어 파마슈티컬즈 앤드 디벨롭먼트, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이언쇼어 파마슈티컬즈 앤드 디벨롭먼트, 인크. filed Critical 아이언쇼어 파마슈티컬즈 앤드 디벨롭먼트, 인크.
Publication of KR20140030158A publication Critical patent/KR20140030158A/ko
Application granted granted Critical
Publication of KR101834033B1 publication Critical patent/KR101834033B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137027522A 2011-03-23 2012-03-23 주의력 결핍 장애 치료용 고체 경구 제약 조성물 Active KR101834033B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161466684P 2011-03-23 2011-03-23
US61/466,684 2011-03-23
US201161561763P 2011-11-18 2011-11-18
US61/561,763 2011-11-18
US201261591129P 2012-01-26 2012-01-26
US61/591,129 2012-01-26
PCT/US2012/030472 WO2012129551A1 (en) 2011-03-23 2012-03-23 Methods and compositions for treatment of attention deficit disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167032196A Division KR20160135373A (ko) 2011-03-23 2012-03-23 주의력 결핍 장애의 치료를 위한 방법 및 조성물

Publications (2)

Publication Number Publication Date
KR20140030158A KR20140030158A (ko) 2014-03-11
KR101834033B1 true KR101834033B1 (ko) 2018-04-13

Family

ID=46879766

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167032196A Ceased KR20160135373A (ko) 2011-03-23 2012-03-23 주의력 결핍 장애의 치료를 위한 방법 및 조성물
KR1020137027522A Active KR101834033B1 (ko) 2011-03-23 2012-03-23 주의력 결핍 장애 치료용 고체 경구 제약 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020167032196A Ceased KR20160135373A (ko) 2011-03-23 2012-03-23 주의력 결핍 장애의 치료를 위한 방법 및 조성물

Country Status (15)

Country Link
US (1) US9028868B2 (enExample)
EP (4) EP4011364B1 (enExample)
JP (7) JP6043785B2 (enExample)
KR (2) KR20160135373A (enExample)
CN (2) CN103608004A (enExample)
AU (3) AU2012230733B2 (enExample)
BR (1) BR112013024401B1 (enExample)
CA (1) CA2830788C (enExample)
DK (3) DK3272342T3 (enExample)
ES (3) ES2644942T3 (enExample)
MX (4) MX2021000431A (enExample)
PT (3) PT2688557T (enExample)
SG (2) SG10201901167SA (enExample)
WO (1) WO2012129551A1 (enExample)
ZA (1) ZA201307649B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119809B2 (en) * 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) * 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) * 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) * 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) * 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2936740C (en) * 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
KR102790656B1 (ko) * 2015-05-04 2025-04-02 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트의 스프링클 제형
PL3324948T3 (pl) * 2015-07-17 2023-06-26 BE Pharbel Manufacturing Wielowarstwowe mikrocząstki uwalniające związek farmaceutycznie aktywny w płynnej postaci dawkowania
US12472149B2 (en) 2015-07-17 2025-11-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
US10383825B2 (en) 2015-08-13 2019-08-20 Temple University—Of the Commonwealth System of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
WO2017173068A1 (en) * 2016-03-30 2017-10-05 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
US9827233B1 (en) * 2016-05-26 2017-11-28 Ovid Therapeutics Inc Methods of treating behavioral syndromes using pipradrol
KR102413459B1 (ko) * 2016-07-06 2022-06-24 듀렉트 코퍼레이션 약물 조성물, 장벽 층 및 약물 층을 갖는 경구 투여 형태
US9931303B1 (en) * 2017-02-06 2018-04-03 Alcobra Ltd. Abuse deterrent formulations of amphetamine
US20180256515A1 (en) * 2017-03-10 2018-09-13 Adare Pharmaceuticals, Inc. Oral amphetamine composition
CA3060366A1 (en) * 2017-04-28 2018-11-01 Astellas Pharma Inc. Pharmaceutical composition for oral administration comprising enzalutamide
US12042566B2 (en) 2017-05-17 2024-07-23 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3459528B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
CN108653243B (zh) * 2018-03-30 2019-03-22 江苏南农高科动物药业有限公司 一种缓释替米考星微囊粉的制备方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662901B1 (en) 2018-12-07 2025-01-01 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
AU2020212036B2 (en) * 2019-01-25 2025-08-28 Ironshore Pharmaceuticals & Development, Inc. Methylphenidate compositions for treatment of attention deficit hyperactivity disorder

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
WO2000023055A1 (en) 1998-10-21 2000-04-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US20040059002A1 (en) 2002-09-24 2004-03-25 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20070264323A1 (en) 2006-05-12 2007-11-15 Shire Llc Controlled dose drug delivery system
US20090220611A1 (en) * 2005-09-30 2009-09-03 Frederic Dargelas Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same
JP2009536945A (ja) * 2006-05-12 2009-10-22 シャイア エルエルシー 制御用量薬物送達システム

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4904476A (en) 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
WO1990009168A1 (en) 1989-02-16 1990-08-23 National Research Development Corporation Dispensing device
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
JP2916978B2 (ja) 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5658590A (en) 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
IT1276689B1 (it) 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
MX9805870A (enExample) 1996-01-22 1999-01-31
AU715183B2 (en) 1996-02-02 2000-01-20 Medeva Europe Limited Process for the preparation of D-threo-(R,R)-methyl phenidate and recycling of undesired enantiomers by epimerisation
DE69710051T2 (de) 1996-03-08 2002-08-14 Medeva Europe Ltd., Slough Auflösungsverfahren von threo-methylphenidate
GB9606417D0 (en) 1996-03-27 1996-06-05 Chiroscience Ltd Asymmetric cyclisation
DK0932388T5 (da) 1996-09-30 2011-06-27 Alza Corp Doseringsform og fremgangsmåde til indgivelse af lægemidler
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP1782798A3 (en) 1996-11-25 2008-05-21 Alza Corporation Ascending-dose dosage form
DK0946151T3 (da) 1996-11-25 2006-08-28 Alza Corp Doseringsform med stigende dosisfrigivelse
AU7847098A (en) 1996-12-13 1998-07-03 Medeva Europe Limited The preparation of enantiomerically-enriched threo- methylphenidate
GB9700912D0 (en) 1997-01-17 1997-03-05 Chiroscience Ltd Resolution
US6210705B1 (en) 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
CA2348871C (en) 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6384020B1 (en) 1999-07-14 2002-05-07 Shire Laboratories, Inc. Rapid immediate release oral dosage form
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
GB9918735D0 (en) * 1999-08-09 1999-10-13 Straken Limited Transdermal patches
US6898455B2 (en) 1999-10-29 2005-05-24 The Mclean Hospital Corporation Method for providing optimal drug dosage
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US6569456B2 (en) 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6520921B1 (en) 2000-06-20 2003-02-18 Eastman Kodak Company Method for determining attention deficit hyperactivity disorder (ADHD) medication dosage and for monitoring the effects of (ADHD) medication
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US20030232890A1 (en) 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20040137062A1 (en) 2001-05-25 2004-07-15 Sham Chopra Chronotherapy tablet and methods related thereto
EA005537B1 (ru) 2001-07-10 2005-04-28 Тева Фармасьютикал Индастриес Лтд. Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US6726624B2 (en) 2002-03-06 2004-04-27 The Mclean Hospital Corporation Method and apparatus for determining attention deficit hyperactivity disorder (adhd) medication dosage and for monitoring the effects of adhd medication on people who have adhd using complementary tests
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
AU2003270349A1 (en) 2002-09-09 2004-03-29 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
EP1589951B1 (en) 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
ES2380622T5 (es) 2003-05-29 2018-05-30 Shire Llc Compuestos de anfetamina resistentes al abuso
US20050031688A1 (en) 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
ES2299995T3 (es) 2004-01-29 2008-06-01 Pfizer, Inc. Derivados de 1-isopropil-2-oxo-1,2-dihidropiridina-3-carboxamida con actividad agonista de receptor 5-ht4.
ES2261006B1 (es) * 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
US20070036843A1 (en) * 2005-01-28 2007-02-15 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
FR2892937B1 (fr) * 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
MX2008014059A (es) 2006-05-09 2008-11-14 Mallinckrodt Inc Formas de dosificacion solida de liberacion modificada en el orden de cero.
FR2901478B1 (fr) * 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
CN1985810A (zh) * 2006-07-28 2007-06-27 中国人民解放军第二军医大学 盐酸哌甲酯缓控释胶囊及其制备方法
KR100888131B1 (ko) 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
CN102973942B (zh) 2006-10-30 2015-08-12 韩诺生物制约株式会社 包含血管紧张素II受体阻断剂和HMG-CoA还原酶抑制剂的控释复合组合物
CN103120653B (zh) 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
AU2009207796B2 (en) * 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
CA2627198A1 (en) 2008-03-27 2009-09-27 Pharmascience Inc. Methylphenidate extended release therapeutic drug delivery system
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
WO2000023055A1 (en) 1998-10-21 2000-04-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US20040059002A1 (en) 2002-09-24 2004-03-25 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20090220611A1 (en) * 2005-09-30 2009-09-03 Frederic Dargelas Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same
US20070264323A1 (en) 2006-05-12 2007-11-15 Shire Llc Controlled dose drug delivery system
JP2009536945A (ja) * 2006-05-12 2009-10-22 シャイア エルエルシー 制御用量薬物送達システム

Also Published As

Publication number Publication date
JP2017128614A (ja) 2017-07-27
JP2024019726A (ja) 2024-02-09
BR112013024401B1 (pt) 2022-01-11
EP4316488A3 (en) 2024-02-28
EP4011364A1 (en) 2022-06-15
SG193587A1 (en) 2013-10-30
ZA201307649B (en) 2014-06-25
AU2016228307A1 (en) 2016-10-06
JP6325148B2 (ja) 2018-05-16
PT4011364T (pt) 2024-02-07
EP2688557B1 (en) 2017-08-23
EP3272342A1 (en) 2018-01-24
JP2020079322A (ja) 2020-05-28
CA2830788A1 (en) 2012-09-27
JP2016117767A (ja) 2016-06-30
DK3272342T3 (da) 2021-06-07
AU2012230733A1 (en) 2013-10-17
MX2022013590A (es) 2022-11-16
JP2018197276A (ja) 2018-12-13
DK2688557T3 (da) 2017-11-27
WO2012129551A1 (en) 2012-09-27
CA2830788C (en) 2016-05-17
EP2688557A4 (en) 2014-09-24
MX2021000431A (es) 2022-10-28
KR20160135373A (ko) 2016-11-25
ES2973539T3 (es) 2024-06-20
AU2012230733B2 (en) 2016-10-20
EP3272342B1 (en) 2021-05-26
AU2018202002B2 (en) 2019-04-04
MX383127B (es) 2025-03-13
ES2883589T3 (es) 2021-12-09
JP2022066315A (ja) 2022-04-28
MX357551B (es) 2018-07-13
BR112013024401A2 (pt) 2017-11-07
SG10201901167SA (en) 2019-03-28
DK4011364T3 (da) 2024-03-18
EP4316488A2 (en) 2024-02-07
PT2688557T (pt) 2017-11-23
ES2644942T3 (es) 2017-12-01
PT3272342T (pt) 2021-07-12
MX2013010920A (es) 2014-08-29
CN103608004A (zh) 2014-02-26
US20120276017A1 (en) 2012-11-01
EP2688557A1 (en) 2014-01-29
AU2018202002A1 (en) 2018-04-12
US9028868B2 (en) 2015-05-12
JP6043785B2 (ja) 2016-12-14
KR20140030158A (ko) 2014-03-11
CN110151731A (zh) 2019-08-23
EP4011364B1 (en) 2023-12-13
JP2014508812A (ja) 2014-04-10

Similar Documents

Publication Publication Date Title
KR101834033B1 (ko) 주의력 결핍 장애 치료용 고체 경구 제약 조성물
US10617651B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
US9034902B2 (en) Methods for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) Methods of treatment of attention deficit hyperactivity disorder
US10292937B2 (en) Methods of treatment of attention deficit hyperactivity disorder
HK40107582A (en) Methods and compositions for treatment of attention deficit disorder
HK40073671B (en) Methods and compositions for treatment of attention deficit disorder
HK40073671A (en) Methods and compositions for treatment of attention deficit disorder

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131018

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151113

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20151113

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160314

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160819

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160314

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20161117

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20160819

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160614

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20151113

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20161128

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20161117

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20160819

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160614

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160314

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20151113

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20161228

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20161128

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20160819

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2016101007311

Request date: 20161228

J301 Trial decision

Free format text: TRIAL NUMBER: 2016101007311; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20161228

Effective date: 20170418

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20170418

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20161228

Decision date: 20170418

Appeal identifier: 2016101007311

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170510

Patent event code: PE09021S01D

GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20171127

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20170421

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180223

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180223

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210127

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20220118

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230117

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240109

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20250106

Start annual number: 8

End annual number: 8